Latanoprost Zentiva

Latanoprost, the active ingredient in Latanoprost Zentiva, is a prostaglandin analog presented as eye drops for ocular use. It lowers intraocular pressure and is indicated for elevated intraocular pressure, open‑angle glaucoma, and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and timely delivery across multiple markets.

Latanoprost is a prostaglandin analog that reduces intraocular pressure in several ocular conditions.

- Elevated intraocular pressure: reduces pressure to prevent optic nerve damage. - Open-angle glaucoma: lowers pressure to slow disease progression and preserve visual field. - Ocular hypertension: decreases pressure to reduce risk of developing glaucoma.

Latanoprost may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Eye redness (hyperemia): mild conjunctival injection. - Increased eyelash growth: longer, thicker lashes. - Eye irritation or foreign‑body sensation. - Darkening of the iris: gradual increase in brown pigmentation.

Serious or Rare Side Effects: - Severe intraocular inflammation (uveitis) requiring medical attention. - Allergic reaction with swelling, itching, or rash around the eye. - Corneal ulcer or keratitis that may threaten vision.

When prescribing Latanoprost, clinicians should consider several precautionary measures to ensure safe use.

- Monitor intraocular pressure: assess response after initiation and adjust therapy as needed. - Avoid use with contact lenses: discontinue lenses at least 15 minutes before and after instillation. - Caution in patients with ocular infections: inflammation may be exacerbated. - Discontinue if severe allergic reaction occurs: seek immediate ophthalmologic evaluation. - Store at room temperature: keep bottle tightly closed, protect from light and freezing.

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops (e.g., ketorolac): may diminish pressure‑lowering effect. - Other prostaglandin analogues: combined use increases risk of pigmentary changes and inflammation. - Systemic prostaglandin therapy: potential additive ocular effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops (e.g., timolol): additive intraocular pressure reduction may cause hypotony. - Carbonic anhydrase inhibitor eye drops (e.g., dorzolamide): monitor for excessive pressure lowering. - Topical corticosteroids: may reduce Latanoprost efficacy; observe pressure trends.